search
Back to results

REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda (REBOA-PPH)

Primary Purpose

Post-partum Hemorrhage

Status
Not yet recruiting
Phase
Phase 3
Locations
Study Type
Interventional
Intervention
REBOA, Resuscitative Endovascular Occlusion of the Aorta
National guidelines
Sponsored by
Centre For International Health
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Post-partum Hemorrhage focused on measuring REBOA, Resuscitative Endovascular Occlusion of the Aorta

Eligibility Criteria

15 Years - 60 Years (Child, Adult)FemaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with life-threatening PPH (PPH and a systolic blood pressure equal to or less than 80 mmHg)
  • Oral consent

Exclusion Criteria:

  • Prior cardiac arrest

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    REBOA

    National guidelines

    Arm Description

    Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)

    Treatment according to Uganda national guidelines for post-partum hemorrhage.

    Outcomes

    Primary Outcome Measures

    Adverse outcome
    The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy

    Secondary Outcome Measures

    Adverse outcome excluding 'inevitable' hysterectomies
    The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids
    Number of AEs and SAEs
    Safety of REBOA assessed by AEs and SAEs
    Maternal death
    The proportion of participants with a maternal death
    Emergency hysterectomy
    The proportion of participants with emergency hysterectomy
    Acute kidney injury
    The proportion of participants with acute kidney injury
    Transfusions
    The number of blood transfusion units
    Hemoglobin
    Post-partum hemoglobin concentration after 1, 2, 3 and 42 days

    Full Information

    First Posted
    October 25, 2022
    Last Updated
    July 4, 2023
    Sponsor
    Centre For International Health
    Collaborators
    Makerere University, Kawempe National Referral Hospital, St. Olavs Hospital, Helse Stavanger HF, University of Liverpool, University of Padova
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05598502
    Brief Title
    REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda
    Acronym
    REBOA-PPH
    Official Title
    Phase III, Open-label, Randomized Clinical Trial to Evaluate Efficacy and Safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in Life-threatening Postpartum Haemorrhage in Reducing Adverse Maternal Outcome in Uganda
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    October 15, 2023 (Anticipated)
    Primary Completion Date
    December 31, 2024 (Anticipated)
    Study Completion Date
    December 31, 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Centre For International Health
    Collaborators
    Makerere University, Kawempe National Referral Hospital, St. Olavs Hospital, Helse Stavanger HF, University of Liverpool, University of Padova

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Background Maternal mortality rates in many low-income countries (LMICs) remain high. The most prominent cause is bleeding after birth, called postpartum hemorrhage (PPH). In a recent report from Uganda, bleeding is the cause of 42% of all maternal deaths in Uganda. Large parts of the monitoring of mothers during active management of third stage of labor is aiming to prevent and early detect PPH and take relevant actions. In spite of this and sometimes in referring mothers to tertiary hospitals, mothers will end up in a challenging condition where quick action is needed. A new method has proven successful for such instances, the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). This is a procedure commonly used for trauma of the lower part of the body but rarely used for PPH. In this trial, it is done by an anesthesiologist where a balloon catheter is inserted via the femoral artery in the groin into the aorta and then being inflated. This will prevent blood from passing to the lower part of the body, including the uterus. It will stop the bleeding and allow for the obstetrician to take relevant action. This is a safe procedure for up to 1 hour of inflation. Objective To assess the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda. Study design, setting and population A phase III, open label, 1:1 randomized clinical trial will be conducted at Kawempe National Referral Hospital, Kampala, Uganda, to evaluate the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care. The inclusion criteria are: a) women with life-threatening PPH and a systolic blood pressure equal to or less than 80 mmHg, b) oral consent. The exclusion criterion is prior cardiac arrest. The sample size of the trial will be 210 participants. Enrolment will follow a group sequential design approach with two interim analyses at 1/3 and 2/3 of the total sample size, and a final analysis with full sample size. Utility of the study It is crucial to explore alternative modalities that could prevent adverse maternal outcomes in life-threatening postpartum hemorrhage in Uganda and the rest of the world.
    Detailed Description
    Background Maternal mortality rates in many low-income countries (LMICs) remain high. The most prominent cause is bleeding after birth, called postpartum hemorrhage (PPH). In a recent report from Uganda, bleeding is the cause of 42% of all maternal deaths in Uganda. Large parts of the monitoring of mothers during active management of third stage of labor is aiming to prevent and early detect PPH and take relevant actions. In spite of this and sometimes in referring mothers to tertiary hospitals, mothers will end up in a challenging condition where quick action is needed. A new method has proven successful for such instances, the Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA). This is a procedure commonly used for trauma of the lower part of the body but rarely used for PPH. In this trial, it is done by an anesthesiologist where a balloon catheter is inserted via the femoral artery in the groin into the aorta and then being inflated. This will prevent blood from passing to the lower part of the body, including the uterus. It will stop the bleeding and allow for the obstetrician to take relevant action. This is a safe procedure for up to 1 hour of inflation. Objective To assess the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda. General objective To assess the efficacy and safety of the use of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care in Uganda. Specific objective - To assess if the proportion of either maternal death and/or emergency hysterectomy, can be decreased from 50 % in the control arm (using standard of care alone) to 30 % or less in the intervention arm (using REBOA). Secondary objectives To assess if the proportion of either maternal death and/or emergency hysterectomy is lower in the intervention arm when excluding 'inevitable' hysterectomies due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids. To assess the safety of REBOA in a national referral hospital in a low-income country like Uganda. To assess if the proportion of maternal deaths is lower in the intervention arm compared to the control arm. To assess if the proportion of emergency hysterectomy is lower in the intervention arm compared to the control arm. To assess if the proportion of women with acute kidney injury is lower in the intervention arm compared to the control arm To assess if the number of blood transfusion units is lower in the intervention arm compared to the control arm. To assess if post-partum hemoglobin concentration is higher in in the intervention arm compared to the control arm. To assess the time to insert the REBOA. Study design, setting and population A parallel group, open-label, individually 1:1 randomized phase III clinical trial will be conducted at Kawempe National Referral Hospital, Kampala, Uganda, to evaluate the efficacy and safety of Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in life-threatening postpartum hemorrhage (PPH) in reducing adverse maternal outcome compared to standard of care. The sample size of the trial will be 210 participants. Enrolment will follow a group sequential design approach with two interim analyses at 1/3 and 2/3 of the total sample size, and a final analysis with full sample size. Results from Norway indicate that REBOA could be an efficient way to prevent post-partum hemorrhage ending in an adverse outcome such as death or emergency hysterectomy. It is not clear whether these results can be reproduced in a low-income setting where PPH is more prevalent, and resources are scarce. The REBOA device could reduce the risk of adverse outcome such as death or emergency hysterectomy. It will be compared to standard of care. Utility of the study It is crucial to explore alternative modalities that could prevent adverse maternal outcomes in life-threatening postpartum hemorrhage in Uganda and the rest of the world.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Post-partum Hemorrhage
    Keywords
    REBOA, Resuscitative Endovascular Occlusion of the Aorta

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 3
    Interventional Study Model
    Parallel Assignment
    Model Description
    Individual randomization
    Masking
    None (Open Label)
    Masking Description
    The study statistician will be masked.
    Allocation
    Randomized
    Enrollment
    212 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    REBOA
    Arm Type
    Experimental
    Arm Description
    Addition of REBOA (Resuscitative Endovascular Occlusion of the Aorta)
    Arm Title
    National guidelines
    Arm Type
    Active Comparator
    Arm Description
    Treatment according to Uganda national guidelines for post-partum hemorrhage.
    Intervention Type
    Device
    Intervention Name(s)
    REBOA, Resuscitative Endovascular Occlusion of the Aorta
    Intervention Description
    The balloon catheter is inserted via the common femoral artery in the groin, accessed under ultrasound guidance due to weak femoral pulses, and the puncture is done by the Seldinger technique. The balloon is inserted along a guidewire 25-30 cm, safely below the renal arteries, to be in the right place to stop pelvic hemorrhage including life-threatening post-partum hemorrhage
    Intervention Type
    Other
    Intervention Name(s)
    National guidelines
    Intervention Description
    Standard management of postpartum hemorrhage according to Uganda national guidelines
    Primary Outcome Measure Information:
    Title
    Adverse outcome
    Description
    The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy
    Time Frame
    42 days
    Secondary Outcome Measure Information:
    Title
    Adverse outcome excluding 'inevitable' hysterectomies
    Description
    The proportion of participants with a composite outcome of either maternal death (=death within 42 days post-partum) or emergency hysterectomy due to either an irreparable uterine rupture, a pathological placenta growing into the uterus (placenta accreta, increta or percreta) or a pathological uterus, such as a bicorne uterus or one with very large fibroids
    Time Frame
    42 days
    Title
    Number of AEs and SAEs
    Description
    Safety of REBOA assessed by AEs and SAEs
    Time Frame
    42 days
    Title
    Maternal death
    Description
    The proportion of participants with a maternal death
    Time Frame
    42 days
    Title
    Emergency hysterectomy
    Description
    The proportion of participants with emergency hysterectomy
    Time Frame
    42 days
    Title
    Acute kidney injury
    Description
    The proportion of participants with acute kidney injury
    Time Frame
    42 days
    Title
    Transfusions
    Description
    The number of blood transfusion units
    Time Frame
    42 days
    Title
    Hemoglobin
    Description
    Post-partum hemoglobin concentration after 1, 2, 3 and 42 days
    Time Frame
    42 days
    Other Pre-specified Outcome Measures:
    Title
    REBOA insertion time
    Description
    Time to insert the REBOA
    Time Frame
    1 day

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    15 Years
    Maximum Age & Unit of Time
    60 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Patients with life-threatening PPH (PPH and a systolic blood pressure equal to or less than 80 mmHg) Oral consent Exclusion Criteria: Prior cardiac arrest
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Thorkild Tylleskar, MD, PhD
    Phone
    004748074410
    Email
    thorkild.tylleskar@uib.no
    First Name & Middle Initial & Last Name or Official Title & Degree
    Josaphat Byamugisha, MD, PhD
    Phone
    00256772580330
    Email
    jbyamugisha@gmail.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Thorkild Tylleskar, MD, PhD
    Organizational Affiliation
    University of Bergen, Norway
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    28355242
    Citation
    Stensaeth KH, Sovik E, Haig IN, Skomedal E, Jorgensen A. Fluoroscopy-free Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) for controlling life threatening postpartum hemorrhage. PLoS One. 2017 Mar 29;12(3):e0174520. doi: 10.1371/journal.pone.0174520. eCollection 2017.
    Results Reference
    background

    Learn more about this trial

    REBOA in Life-threatening Postpartum Hemorrhage (PPH) in Uganda

    We'll reach out to this number within 24 hrs